Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concor plus amlodipine versus amlodipine monotherapy in uncontrolled essential hypertension
2019-000751-13Phase 3Completed
- Sponsor
- Fundacja Centrum Rozwoju Medycyny
- Start
- Mar 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bisoprolol, amlodipine and Levamlodipine in essential hypertension (2 arms), sponsored by Fundacja Centrum Rozwoju Medycyny. Primary endpoint: Change in systolic blood pressure from baseline after 8 weeks of treatment. Started Mar 2019; status: completed.
02
Drugs
bisoprololamlodipineLevamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2019-000751-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000751-13.